Patent intelligence · US
US 9982259
Transthyretin allele selective UNA oligomers for gene silencing
Transthyretin allele selective UNA oligomers for gene silencing
Patent details — US 9982259
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 29, 2018
- Expiration
- May 24, 2038
- Applicant
- ARCTURUS THERAPEUTICS, INC.
- Claims
- 29
- CPC classes
- A61K, A61K31/685, A61K31/713, A61K9/127
Quick answer
US 9982259 (Transthyretin allele selective UNA oligomers for gene silencing) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted May 29, 2018. Expires May 24, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARCTURUS THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/685, A61K31/713, A61K9/127, A61P, A61P25/00
More from ARCTURUS THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398379
Compositions and methods for treating ornithine transcarbamylase deficiency
granted -
US 12390524
Compositions and methods for inducing immune responses
granted -
US 12351834
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
granted -
US 12290567
Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates
granted -
US 12286395
Method of synthesis of an ionizable cationic lipid
granted -
US 12220485
Method of making lipid-encapsulated RNA nanoparticles
granted -
US 12220455
Coronavirus vaccine compositions and methods
granted -
US 12178921
Method of lyophilizing lipid nanoparticles
granted
Frequently asked questions
What is US patent 9982259?
US 9982259 (Transthyretin allele selective UNA oligomers for gene silencing) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted May 29, 2018. Expires May 24, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9982259?
ARCTURUS THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.
When does US 9982259 expire?
Our index shows an expiration date of May 24, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.